HeyJaredSaša Janković
- Indexed articles, last 90 days
- 2
- Latest publication
- Sep 18, 2026
- Outlet visibility, for The Pharmaceutical Journal
- Top 1M sites
- Earliest in this view
- Aug 13, 2026
Latest articles
Everything you need to know about the push for microbiome medicine development (opens the original)
Read excerpt
Microbiome-based medicinal products (MBMPs) contain microorganisms as the active product and treat disease by modulating, restoring or replacing the human biome. They also fall under the existing UK medicines regulatory framework as set out in the Human Medicines Regulations 2012. Despite the absence of UK marketing authorisations for MBMPs, faecal microbiota transplantation (FMT) is available as a treatment as part of clinical trials and as an unlicenced medicine — often for recurrent Clostridi
A faster route to rare disease treatments: the MHRA’s proposals (opens the original)
Read excerpt
Of an estimated 10,000 rare diseases, the vast majority still have no effective therapy, according to the Medicines and Healthcare products Regulatory Agency (MHRA), which puts the cost of delayed diagnosis at £340m per year and health-related disability costs at a further £4.7bn. However, up to 3.5 million people in the UK living with rare diseases could access treatments more easily via a new framework proposed by the MHRA in May 2026. The regulator puts the current route to marketing authoris
Publishing over time
Last 90 days. Choose a month to open its work.
Recurring subjects
Named in the text we hold. One piece can cover several.
Audience
Top 1M sites
For The Pharmaceutical Journal, the outlet · Measured Aug 1, 2026
Website popularity band, not a count of readers or article views.
About this data
Counts cover the work we have indexed. Tone needs enough text and a confident classification. Excerpts and episode notes are not full articles or transcripts.
Identity or attribution wrong? Suggest a correction.